Petrelintide
Also called ZP8396
Subcutaneous (under the skin)Human study reference
Research reference
Human study
Petrelintide phase 1 multiple-dose study
Once weekly, with increases every 2 weeks toward separate 2.4, 4.8 or 9 mg targets
16 weekly doses; separate earlier cohorts received 6 weekly doses
Olsen et al., Diabetes Obesity and Metabolism (2026) ↗When results may show
- When change was measured
- Weight was measured after 16 weeks. Early tolerability and exposure data are not a validated personal dose-selection rule.
- When to assess
- 16 weekly doses; separate earlier cohorts received 6 weekly doses
- Conditions and limitations
- Adults with overweight or obesity in the 16-week study part. The abstract reports target groups, not a complete per-increase starter schedule. No missing steps are invented.
- When to stop
- The measured study window is not a validated personal quit rule. Do not increase or prolong exposure because an expected result is absent; severe or persistent reactions need prompt clinical review.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Vial arithmetic
Published research contexts for Petrelintide describe 0.3–2.4 mg per administration. Descriptive only, not a recommendation.
Modelled level — once a week
1× is the peak after a single dose.
- Steady-state peak
- 1.98× single dose
- Time to steady state
- 35.0days
- Administrations
- 1/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Olsen et al., Diabetes Obesity and Metabolism (2026)The abstract reports target groups, not a complete per-increase starter schedule. No missing steps are invented.
Next steps
Petrelintide beginner guideOpen Petrelintide planning worksheetEstimate Petrelintide vial costTrack Petrelintide notes